Mary A. Markiewicz

Mary A. Markiewicz

Auto-generated profile, based on publicly available information

Mary A. Markiewicz

Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center , Kansas City, KS 66160

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2003 in Science
Verified
Journal Article
Closed access
PDF file
KLKyeong-Hee Lee
Kyeong-Hee Lee
ADAaron R. Dinner
Aaron R. Dinner
CTChun Tu
Chun Tu
GCGabriele Campi
Gabriele Campi
SRSubhadip Raychaudhuri
Subhadip Raychaudhuri
ASAndrey S. Shaw
Andrey S. Shaw
The immunological synapse is a specialized cell-cell junction between T cell and antigen-presenting cell surfaces. It is characterized by a central cluster of antigen receptors, a ring of integrin family adhesion molecules, and temporal stability over hours. The role of this specific organization in signaling for T cell activation has been controversial. We use in vitro and in silico experiments to determine that the immunological synapse acts as a type of adaptive controller that both boosts T cell receptor triggering and attenuates strong signals.

17 March 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MMMary A. Markiewicz
Mary A. Markiewicz
CGCristina Girao
Cristina Girao
JOJoseph T. Opferman
Joseph T. Opferman
JSJiling Sun
Jiling Sun
QHQinghui Hu
Qinghui Hu
PAPhilip G. Ashton-Rickardt
Philip G. Ashton-Rickardt
How memory T cells are maintained in vivo is poorly understood. To address this problem, a male-specific peptide (H-Y) was identified and used to activate female anti-H-Y T cells in vitro. Anti-H-Y T cells survived in vivo for at least 70 days in the absence of antigen. This persistence was not because of the intrinsic ability of memory T cells to survive in vivo . Instead, the survival and function of adoptively transferred memory cells was found to require transporter of antigen protein 1-dependent expression of self-peptide/major histocompatibility complex class I molecules in recipient animals. Therefore, it appears that the level of T cell receptor engagement provided by transporter of antigen protein 1-dependent, self-peptide/major histocompatibility complexes is sufficient to maintain the long-term survival and functional phenotype of memory cells in the absence of persistent antigen. These data suggest that positive selection plays a role not only in T cell development but also in the maintenance of T cell memory.

1 September 2008 in Immunity
Verified
Journal Article
Closed access
SČSašo Čemerski
Sašo Čemerski
JDJayajit Das
Jayajit Das
Emanuele GiurisatoEmanuele Giurisato
Emanuele Giurisato
MMMary A. Markiewicz
Mary A. Markiewicz
PAPaul M. Allen
Paul M. Allen
ASAndrey S. Shaw
Andrey S. Shaw

1 September 2005 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MMMary A Markiewicz
Mary A Markiewicz
LCLeonidas N. Carayannopoulos
Leonidas N. Carayannopoulos
ONOlga V. Naidenko
Olga V. Naidenko
KMKen Matsui
Ken Matsui
WBW. Richard Burack
W. Richard Burack
ASAndrey S. Shaw
Andrey S. Shaw
Multiple studies have demonstrated that the NK cell activating receptor NKG2D can function as a costimulatory receptor for both mouse and human CD8+ T cells. However, it has recently been suggested that stimulation through NKG2D is insufficient for costimulation of CD8+ T cells. To aid in the delineation of NKG2D function in CTL responses, we investigated whether stimulation of NKG2D by the natural ligand RAE1ε was able to costimulate effector functions of a murine CTL line generated from DUC18 TCR transgenic mice. We found that NKG2D was able to costimulate DUC CTL responses and did so in a manner similar to CD28 costimulation. The T cells exhibited increased proliferation, IFN-γ release, and cytotoxicity when presented antigenic peptide by P815 cells expressing RAE1ε or B7-1 compared with untransfected P815. In addition, both RAE1ε and B7-1 enhanced Ag-independent IFN-γ secretion in response to IL-12 and IL-18 by DUC CTL. However, only costimulation through CD28 allowed for DUC CTL survival upon secondary stimulation, whereas ligation of NKG2D, but not CD28, induced DUC CTL to form an immune synapse with target cells in the absence of TCR stimulation. Understanding the outcomes of these differences may allow for a better understanding of T cell costimulation in general.

23 May 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Samuel AchilefuSamuel Achilefu
Samuel Achilefu
SBSharon Bloch
Sharon Bloch
MMMary A. Markiewicz
Mary A. Markiewicz
TZTuoxiu Zhong
Tuoxiu Zhong
YYYunpeng Ye
Yunpeng Ye
KLKexian Liang
Kexian Liang
Integrins mediate many biological processes, including tumor-induced angiogenesis and metastasis. The arginine–glycine–aspartic acid (RGD) peptide sequence is a common recognition motif by integrins in many proteins and small peptides. While evaluating a small library of RGD peptides for imaging αVβ3integrin (ABI)-positive tumor cell line (A549) by optical methods, we discovered that conjugating a presumably inactive linear hexapeptide GRDSPK with a near-infrared carbocyanine molecular probe (Cypate) yielded a previously undescribed bioactive ligand (Cyp-GRD) that targets ABI-positive tumors. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay with A549 cells showed that Cyp-GRD was not cytotoxic up to 100 μM in cell culture. The compound was internalized by cells, and this internalization was blocked by coincubation with a cyclic RGD peptide (cyclo[RGDfV], f isd-phenylalanine) that binds ABI with high affinity.In vivo, Cyp-GRD selectively accumulated in tumors relative to surrounding normal tissues. Blocking studies with cyclo[RGDfV] inhibited thein vivouptake of Cyp-GRD, suggesting that both compounds target the same active site of the protein. A strong correlation between the Cyp-GRD peptide and mitochondrial NADH concentration suggests that the new molecule could also report on the metabolic status of cellsex vivo. Interestingly, neither a Cypate-labeled linear RGD peptide nor an111In-labeled DOTA-GRD conjugate was selectively retained in the tumor. These results clearly demonstrate the synergistic effects of Cypate and GRD peptide for molecular recognition of integrin expression and suggest the potential of using carbocyanines as optical scaffolds for designing biologically active molecules.

12 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
RPRanjan Preet
Ranjan Preet
AIAtiqul Islam
Atiqul Islam
JSJiyoung Shim
Jiyoung Shim
GRGaneshkumar Rajendran
Ganeshkumar Rajendran
AMAmrita Mitra
Amrita Mitra
JZJun Zhang
Jun Zhang
Lung cancer is the leading cause of cancer-related deaths worldwide. Although immunotherapy such as anti-programmed death-1 and its ligand 1 (PD-1/L1) is a standard treatment for advanced non-small cell lung cancer (NSCLC), many patients do not derive benefit directly. Several studies have elucidated new strategies to improve the antitumor immune response through gut microbiota modulation. However, it remains largely debatable regarding how gut microbiota remotely affect lung cancer microenvironment and subsequently modulate immunotherapy response. Here we show that commensal Bifidobacterium-derived extracellular vesicles (Bif.BEVs) can modulate the therapeutic effect of anti-PD-1 therapy in NSCLC. These Bif.BEVs are up-taken by lung cancer cells predominantly via dynamin-dependent endocytosis and upregulate PD-L1 expression through TLR4-NF-κB pathway. They also efficiently penetrate murine intestinal and patient-derived lung cancer organoids. Oral gavage of these Bif.BEVs result in their accumulation in tumors in mice. Using a syngeneic mouse model, Bif.BEVs are found to synergize the anti-tumor effect of anti-PD-1 via modulation of key cytokines, immune response and oncogenic pathways, and increase in tumor-infiltrating CD8+ T cells. Our study therefore identifies a link between Bif.BEVs and the tumor microenvironment, providing an alternative mechanism to explain how gut microbiota can influence immunotherapy response, particularly in tumors located anatomically distant from the gut.